Group 1 - The core viewpoint of the article is that the company reported a significant decline in revenue and profit for the first half of 2025, primarily due to the inclusion of two products in centralized procurement [1] - The company's total revenue for the first half of 2025 was RMB 13.273 billion, representing an 18.5% year-on-year decrease [1] - The reported profit attributable to shareholders was RMB 2.548 billion, a decrease of 15.6% compared to the previous year [1] Group 2 - The basic earnings per share were RMB 0.2229, and the board declared an interim dividend of HKD 0.14 per share for the 2025 fiscal year [1] - The revenue from the prescription drug business was RMB 10.248 billion, down 24.4% year-on-year [1] - Revenue from raw material products increased by 11.9% to RMB 2.075 billion, while revenue from functional foods and other businesses grew by 8.0% to RMB 0.951 billion [1]
石药集团(01093.HK)上半年纯利跌15.6%至25.48亿元 中期息每股14港仙